Aripiprazole: In adolescents with schizophrenia

Pediatric Drugs

Volumn 9, Issue 6, 2007, Pages 419-423

  Sanford, Mark ^a   Keating, Gillian M ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE

Author keywords

Adis Drug Profiles; Aripiprazole, adverse reactions; Aripiprazole, pharmacodynamics; Aripiprazole, pharmacokinetics; Aripiprazole, therapeutic use; Schizophrenia, treatment

Indexed keywords

ARIPIPRAZOLE; PLACEBO;

ADOLESCENT DISEASE; AKATHISIA; CLINICAL TRIAL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYNDROME; HUMAN; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; TREATMENT RESPONSE; TREMOR; WEIGHT CHANGE; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; HUMANS; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA;

EID: 36749094554     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200709060-00009     Document Type: Review

References (16)

1. Gillberg C, Wahlstrom J, Forsman A, et al. Teenage psychoses: epidemiology, classification and reduced optimality in the pre-, peri-, and neonatal periods. J Child Psychol Psychiatry 1986 Jan; 27 (1): 87-98
2. Masi G, Mucci M, Pari C. Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 2006; 20 (10): 841-66
3. Lenior ME, Dingemans PMAJ, Schene AH, et al. Predictors of the early 5-year course of schizophrenia: a path analysis. Schizophr Bull 2005; 31 (3): 781-91
4. McClellan J, Werry J. Summary of the practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2000 Dec; 39 (12): 1580-2
5. Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20 (5): 389-409
6. Kumra S, Oberstar JV, Sikich L, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull. Epub 2007 Oct 8
7. Toren P, Ratner S, Laor N, et al. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004; 27 (14): 1135-56
8. Bristol-Myers Squibb Company and Otsuka America Pharmaceutical Inc. Abilify® (aripiprazole) tablets prescribing information [online]. Available from URL: http:www.abilify.com [Accessed 2007 Nov 19]
9. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64 (15): 1715-36
10. Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006 Feb; 39 Suppl. 1: S21-5
11. Findling RL, Nyilas M, Auby P, et al. Tolerability of aripiprazole in the treatment of adolescents with schizophrenia [abstract no. NR741 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA)
12. Correll CU, Mughal T, Parikh U, et al. Insulin resistance in treatment-naive youngsters treated with novel antipsychotics [abstract no. NR654 plus poster]. American Psychiatric Association Annual Meeting; 2005 May 21-26; Atlanta (GA)
13. Blumer JL, Findling R, Kauffman R, et al. Pharmacokinetics, tolerability and safety of aripiprazole in children and adolescents with conduct disorder [abstract no. MPI-3]. Clin Pharmacol Ther 2002 Feb; 71: 5A
14. Findling RL, Auby P, Nyilas M, et al. Pharmacokinetics and tolerability of aripiprazole in children and adolescents with major psychiatric diagnoses [abstract no. NR654 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
15. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004 Feb; 44 (2): 179-87
16. Robb AS, Auby P, Nyilas M, et al. Efficacy of aripiprazole in the treatment of adolescents with schizophrenia [abstract no. NR742 plus poster]. 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego (CA)